巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Larimar Therapeutics

LRMR
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Larimar Therapeutics - 延遲價格・最後更新於 14/01 12:15
最高位
9.300
最低位
8.860
開市價
--
前收市價
9.190
成交量(千)
0.50
成交額(百萬)
0.05
買入
--
賣出
--
每手股數
--
市值(百萬)
163.64
市盈率
--
息率
--
差價
--
52週高低
20.830 - 7.000
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Larimar Therapeutics
證券代碼
LRMR.US
所屬板塊
Biotechnology
公司業務
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
發行量
15367730
公司總部
Three Bala Plaza East, Suite 506
公司網址
https://www.larimartx.com
公司電話
+1 844 511-9056
暫無內容

關於

Larimar Therapeutics(LRMR.US)所屬的行業板塊為Biotechnology。
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
詳細公司背景可參考: https://www.larimartx.com